11-Sept-2026 17:32:40

AUROBINDO PHARMA : US FDA INSPECTION AT UNIT-IV CONCLUDES WITH ZERO OBSERVATIONS

• Apitoria Pharma Private Limited, a wholly owned subsidiary, underwent a US FDA inspection at its Unit-IV API manufacturing facility from September 07 to September 11, 2026. • The inspection concluded with zero observations. • Impact: Positive (Regulatory compliance milestone achieved with zero observations)

Aurobindo Pharma Limited

← Back to feed